2.48
+0.07(+2.90%)
Currency In USD
| Previous Close | 2.41 |
| Open | 2.38 |
| Day High | 2.53 |
| Day Low | 2.36 |
| 52-Week High | 5.5 |
| 52-Week Low | 1.11 |
| Volume | 329,966 |
| Average Volume | 936,616 |
| Market Cap | 48.79M |
| PE | -1.73 |
| EPS | -1.43 |
| Moving Average 50 Days | 3.37 |
| Moving Average 200 Days | 2.68 |
| Change | 0.07 |
If you invested $1000 in Annovis Bio, Inc. (ANVS) since IPO date, it would be worth $258.6 as of February 21, 2026 at a share price of $2.48. Whereas If you bought $1000 worth of Annovis Bio, Inc. (ANVS) shares 5 years ago, it would be worth $74.77 as of February 21, 2026 at a share price of $2.48.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease
GlobeNewswire Inc.
Feb 12, 2026 1:00 PM GMT
MALVERN, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such
Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients
GlobeNewswire Inc.
Dec 18, 2025 9:35 PM GMT
Enrollment will begin in January 2026 Participants will be treated with buntanetap for 36 months The study aims to enroll 500 patients MALVERN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a la
Annovis to Host Corporate Update Webinar on January 28, 2026
GlobeNewswire Inc.
Dec 16, 2025 1:00 PM GMT
MALVERN, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease